Navigation Links
Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial
Date:1/23/2009

SHORT HILLS, N.J., Jan. 23 /PRNewswire-USNewswire/ -- Peter T. Wilderotter, president and CEO of the Christopher & Dana Reeve Foundation, issued the following statement today in response to FDA clearance of Geron's human clinical trial of embryonic stem cell-based therapy:

"This is an exciting first step for Geron and for spinal cord injured patients whose lives may improve due to advances in medical research. There has been so much speculative and unsubstantiated information about the use of stem cells in spinal cord injury; it is important to study these cells in a rigorously designed clinical trial that is monitored by the FDA."

Wilderotter continued, "Christopher and Dana Reeve brought national attention to this issue and they gave voice to all those who are suffering the devastating physical, emotional and financial impact of challenging neurological conditions. Their belief in the promise of stem cell research became a part of their lasting legacy."

Shortly before his death, Christopher Reeve wrote, "It is our responsibility to do everything possible to protect the quality of life of the present and future generations...No obstacle should stand in the way of responsible investigation of their [stem cells] possibilities."

Wilderotter concluded, "This is the dawn of basic research being translated into human clinical trials for people living with spinal cord injury. We are hopeful that what is learned from the results will enable us to move forward with therapies for people living with spinal cord injuries."

About the Reeve Foundation

The Christopher and Dana Reeve Foundation is dedicated to curing spinal cord injury by funding innovative research, and improving the quality of life for people living with paralysis through grants, information and advocacy. For more information, and to review the entire list of Quality of Life grant recipients, please visit our website at www.ChristopherReeve.org or call 800-225-0292.


'/>"/>
SOURCE The Christopher and Dana Reeve Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
4. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
5. Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
9. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
10. HEALTHeCAREERS Network Pledges $15,000 to ASRT Foundation for Professional Healthcare Training
11. Stem Cell Sciences Enters into Services Agreement with Huntingdons Disease Research Group, CHDI Foundation Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):